Search PubMed⌕ Search

Biomedical subjects

K Fuxe

Publications and source records attributed to K Fuxe.

At least 235 records · Page 13Linked to original sources
PubMed1994

Evidence for an antagonistic angiotensin II/alpha 2-adrenoceptor interaction in the nucleus tractus solitarii.

Interactions between alpha 2-adrenoceptors and angiotensin II receptors were evaluated in the nucleus tractus solitarii of the rat by means of quantitative receptor autoradiography and cardiovascular analysis. In binding experiments using l-noradrenaline to compete for [3H]p-aminoclonidine binding sites, angiotensin II (1 nM) increased the IC50 value of l-noradrenaline by 50%. The angiotensin AT1 receptor antagonist, DUP753 (losartan), not only blocked this action but also decreased the IC50 value of l-noradrenaline. The modulatory effect of angiotensin II was also evaluated after addition of both DUP753 and PD123319, an angiotensin AT2 receptor antagonist, and counteraction of the reduction in the IC50 value of l-noradrenaline was observed. In saturation experiments angiotensin II increased the KD and Bmax values of [3H]p-aminoclonidine binding sites, compatible with possible uncoupling of the alpha 2-adrenoceptors. Cardiovascular analysis demonstrated that a threshold dose of angiotensin II (0.05 pmol) counteracted the vasodepressor effect produced by an ED50 dose of l-adrenaline, l-noradrenaline or clonidine coinjected in the nucleus tractus solitarii. DUP753 fully blocked this in vivo modulation of alpha 2-adrenoceptors by angiotensin II. These findings suggest the existence of an antagonistic angiotensin AT1/alpha 2-adrenoceptor interaction in the nucleus tractus solitarii. Therefore, it can be surmised that the activation of angiotensin II AT1 receptors may reduce the transduction of the alpha 2-adrenoceptors and thus the alpha 2-mediated vasodepressor responses.

Adrenergic alpha-Antagonists↗
PubMed1994

Generalized presence of a PEC-60-like peptide in catecholamine neurones.

PEC-60, a 60-residue intestinal peptide structurally related to the pancreatic secretory type of trypsin inhibitor, has been isolated, characterized and molecularly cloned. It shows biological activity as a hormone in both the gastrointestinal tract and in the immune system. We now report immunohistochemical evidence suggesting its neural localization exclusively within central and peripheral catecholamine (CA) neurones. PEC-60-like immunoreactivity was present in cell bodies, dendrites and nerve terminals of virtually all catecholamine neurones examined and including the noradrenergic gland cells of the adrenal medulla. PEC-60-like immunoreactivity was not seen, however, within the tyrosine hydroxylase-positive but CA-negative arcuate neurones producing growth hormone releasing hormone. The findings open up the possibility that a PEC-60-like peptide may represent a generalized co-transmitter in the peripheral and central CA neurones.

Animals↗
PubMed1994

Chronic nicotine treatment counteracts dopamine D2 receptor upregulation induced by a partial meso-diencephalic hemitransection in the rat.

To further elucidate the previously demonstrated protective actions of nicotine on lesioned nigrostriatal dopamine (DA) systems (Janson and Møller, Neuroscience, 57 (1993) 931-941), the present receptor binding experiments were carried out. Rats were partially hemitransected at the meso-diencephalic junction and the effects of chronic continuous (-)nicotine treatment (osmotic pumps s.c., 0.125 mg/kg/h, 14 days) on [3H]N-propylnorapomorphine ([3H]NPA) and [3H]methylcarbamylcholine ([3H]MCC) binding were investigated in striatal coronal sections to study the agonist binding sites of DA D2 receptors and nicotinic cholinoceptors, respectively. In saline-treated but not in nicotine-treated rats, the lesion led to an increased Bmax value of [3H]NPA binding. The Bmax value of [3H]MCC binding was increased by nicotine treatment and decreased by the partial hemitransection. These results indicate that chronic nicotine treatment counteracts the lesion-induced upregulation of the high-affinity agonist binding site of the DA D2 receptor, which may be explained by an increased presence of DA via a protective effect of nicotine on neostriatal DA terminals. This action of nicotine may be of interest in the treatment of neurodegenerative diseases such as Parkinson's disease.

Animals↗
PubMed1994

Selective modulation of the NPY receptors of the Y2 subtype by alpha 2 receptors in the nucleus tractus solitarii of the rat. A cardiovascular and quantitative receptor autoradiographical analysis.

The modulation of neuropeptide Y (NPY) receptors by alpha 2 receptors in the nucleus tractus solitarii (Sol) of the rat was evaluated using quantitative receptor autoradiography and measurements of mean arterial blood pressure and heart rate. The receptor autoradiographical experiments showed that clonidine (10 nM), a selective alpha 2 receptor agonist, induced a 59% increase in the B0 value and a 47% decrease in the IC50 value of NPY(1-36) when competing for [125I]peptide YY ([125I]PYY)-binding sites in the presence of [Leu31, Pro34]NPY (100 nM), a selective NPY Y1 receptor agonist, to block the binding to NPY Y1 receptors. In contrast, when NPY(13-36) (300 nM), a selective NPY Y2 receptor agonist, was used to block the binding to NPY Y2 receptors, clonidine (1-30 nM) did not affect the B0 value and the IC50 value of NPY(1-36) when competing for [125I]PYY-binding sites, suggesting that the stimulation of alpha 2 receptors can selectively increase the affinity of NYP(1-36) for the NPY Y2 receptor. Microinjections of threshold doses of adrenaline or clonidine into the Sol not only counteracted the vasopressor action of a close to ED50 dose of coinjected NPY(13-36), but also changed the vasopressor and tachycardic response produced by NPY(13-36) into a vasodepressor and bradycardic response. However, threshold doses of adrenaline or of clonidine microinjected into the Sol did not modify the vasodepressor responses to a close to ED50 dose of NPY(1-36) or of [Leu31, Pro34]NPY.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1994

PEC-60 increases dopamine but not GABA release in the dorsolateral neostriatum of the halothane anaesthetized rat. An in vivo microdialysis study.

The effect of striatal perfusion with the intestinal peptide PEC-60 on endogenous dopamine (DA) and gamma-aminobutyric acid (GABA) release in the dorsolateral striatum and GABA release in the globus pallidus was monitored using in vivo microdialysis in the halothane anaesthetized rat. The results show that PEC-60 (100 nM) increases DA release in the dorsolateral striatum without influencing GABA release in the dorsolateral striatum or in the globus pallidus. In addition, PEC-60 failed to influence the extracellular striatal 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) levels. The PEC-60 induced increase in striatal DA was abolished by the addition of tetrodotoxin (1 microM) to the perfusion medium. These data suggest that PEC-60 plays a role in modulating striatal DA release but not DA metabolism and that this effect is primarily targeted on the presynaptic DA terminals of the nigrostriatal DA pathway rather than on the postsynaptic striatopallidal GABA projection neurons in the dorsolateral striatum.

3,4-Dihydroxyphenylacetic Acid↗
PubMed1994

Strong effects of NT/NN peptides on DA D2 receptors in rat neostriatal sections.

Quantitative receptor autoradiography was performed to test the effects of neurotensin (NT)/neuromedin N (NN) peptides on dopamine (DA) D2 receptors in rat neostriatal sections. Competition experiments showed that 10 nM of NT, 10 nM of NN, and 1 nM of the C-terminal NT-(8-13) fragment produced a 2-fold increase in the IC50 value and a 20% decrease in the B0 value of DA for the D2 antagonist [125I]iodosulpride binding sites. The results demonstrate a stronger reduction in the affinity of DA for neostriatal D2 receptors by the NT/NN peptides in brain sections compared with membrane preparations indicating the possible involvement of cytoplasmic factors and/or a demand for a more intact membrane structure in these receptor-receptor interactions. Further evidence for the hypotheses that the C-terminal NT fragments may be among the major ligands for the neostriatal NT receptors and that the neostriatal NT receptors may be a new subtype of NT receptor has been obtained.

Animals↗
PubMed1994

Dopamine D1 receptors are involved in the modulation of D2 receptors induced by cholecystokinin receptor subtypes in rat neostriatal membranes.

The action of cholecystokinin octapeptide (CCK-8) on rat neostriatal dopamine (DA) D2 receptors was evaluated in membrane binding experiments. 0.1 nM of CCK-8 increased the Kd value of the D2 agonist [3H]N-propylnorapomorphine (NPA) binding sites by 42%. The CCKB antagonist PD134308 blocked this action. Kinetic analysis demonstrated that this effect of CCK-8 was related to a reduction by 45% of the association rate constant of [3H]NPA. In contrast, 1 nM of CCK-8 decreased the KH and the KL values of DA for the D2 antagonist [3H]raclopride binding sites by 56% and 50%, respectively. Both the CCKA antagonist L364718 and the CCKB antagonist PD134308 blocked this effect. The D1 antagonist SCH23390 counteracted the CCK-8 induced decrease in the KH and the KL values of DA, and allowed 1 nM of CCK-8 to produce a significant increase in the IC50 value of NPA for the [3H]raclopride binding sites. These results indicate that CCK-8 can reduce the affinity of the neostriatal D2 agonist binding sites, but increase the affinity of D2 receptors for DA. D1 receptors may exert a switching role in the modulation of the neostriatal D2 receptors by the CCK receptors.

Animals↗
PubMed1994

Intracisternally injected galanin-(1-15) modulates the cardiovascular responses of galanin-(1-29) and the 5-HT1A receptor agonist 8-OH-DPAT.

In view of the demonstration of specific binding sites for [125I]galanin-(1-15) in several brain areas including the nucleus of the solitary tract, possibly indicating the existence of multiple galanin receptor subtypes, the effects of intracisternal injections of galanin-(1-15) on cardiovascular parameters were studied. The effects of co-injections of galanin-(1-15) and galanin-(1-29) and co-injections of galanin-(1-15) and the 5-HT1A receptor agonist 8-OH-2-(di-n-propylamino)tetralin (8-OH-DPAT) were also evaluated. Galanin-(1-15) produced a significant increase in mean arterial blood pressure (maximum effect 10% at 3 nmol of galanin-(1-15)) and in heart rate (maximum effect 12% at 1 nmol). When threshold doses of galanin-(1-15) (0.1 nmol) and galanin-(1-29) (3 nmol) were injected simultaneously they elicited an increase in mean arterial blood pressure. The vasodepressor response induced by an ED50 dose of 8-OH-DPAT (6 nmol) was not modulated by a threshold dose of galanin-(1-15), but the increase in heart rate area induced by galanin-(1-15) alone was no longer observed. When threshold doses of both galanin-(1-15) and 8-OH-DPAT (0.3 nmol) were co-injected a vasodepressor response developed and on heart rate a tachycardic response was seen in the peak effects and the overall tachycardic response induced by galanin-(1-15) was sustained. The results show a different role for galanin-(1-15) as compared with galanin-(1-29) in central cardiovascular control.(ABSTRACT TRUNCATED AT 250 WORDS)

8-Hydroxy-2-(di-n-propylamino)tetralin↗
PubMed1994

Coinjections of NPY(1-36) or [Leu31,Pro34]NPY with adrenaline in the nucleus tractus solitarius of the rat counteract the vasodepressor responses to adrenaline.

The cardiovascular effects of adrenaline microinjected alone or together with neuropeptide Y (NPY) receptor agonists into the nucleus tractus solitarius (Sol) of the anaesthetized rat have been investigated in order to evaluate NPY/adrenergic receptor interactions. In the dose range 0.05-20 nmol, adrenaline microinjected unilaterally into the Sol produced significant dose-related reductions in mean arterial blood pressure and heart rate. The vasodepressor action of a close to ED50 dose of adrenaline (0.5 nmol) was significantly counteracted by a threshold dose of NPY (1-36) (1 pmol) and of the NPY Y1 receptor agonist [Leu31,Pro34]NPY (2.5 pmol) microinjected into the Sol, but not by a threshold dose of NPY(13-36)(50 fmol), a selective Y2 receptor agonist. The present study provides evidence for an antagonistic NPY Y1/adrenergic receptor interaction in the Sol of the rat, involved in cardiovascular regulation.

Animals↗
PubMed1994

6-hydroxy-dopamine treatment counteracts the reduction of cortical GABA release produced by the vigilance promoting drug modafinil in the awake freely moving guinea-pig.

The effects of acute and repeated treatments with modafinil (30 mg/kg, s.c.) alone or after i.c.v. 6-hydroxy-dopamine injection were studied on cortical GABA release as well as on cortical/striatal catecholamine levels in awake freely moving guinea pig. The results show that repeated daily modafinil treatment produces a similar but short-lasting reduction of GABA outflow compared with acute administration. A significant reduction of cortical basal GABA outflow was observed in animals treated with 6-hydroxy-dopamine, which was maintained also after modafinil treatments. Furthermore, after the 6-hydroxy-dopamine treatment, modafinil fails to inhibit cortical GABA release. The depleting action of the toxin, 17% reduction of neostriatal dopamine levels and 35% of noradrenaline levels in the parietal cortex, was not influenced by repeated modafinil treatment. The catecholaminergic telencephalic networks therefore seem essential for the elicitation of the inhibitory effects of modafinil on GABA release.

Animals↗
PubMed1994

Dopamine D1 and D2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by N-methyl-D-aspartic acid.

The effects of local perfusion with the dopamine D1 receptor antagonist SCH 23390 and the dopamine D2 receptor antagonist raclopride on basal and N-methyl-D-aspartate (NMDA) stimulated dopamine, gamma-aminobutyric acid (GABA) and glutamate levels in the dorsolateral striatum were monitored using in vivo microdialysis in the halothane anaesthetized rat. Local perfusion (90 min) with SCH 23390 and raclopride (1 and 10 microM) dose dependently increased basal striatal dopamine release whereas GABA and glutamate dialysate levels were unaffected. Local perfusion (10 min) with the 1 mM concentration of NMDA increased striatal dopamine, GABA and glutamate outflow. However, when perfused together with SCH 23390 (1 microM) NMDA inhibited glutamate efflux. Moreover, in the presence of SCH 23390 (10 microM) the NMDA induced rise in dopamine and GABA levels was partly prevented. On the other hand, raclopride 1 microM enhanced the NMDA stimulated GABA efflux while at 10 microM it partly counteracted the NMDA induced dopamine release. These data demonstrate that NMDA induced changes in striatal neurotransmitter outflow are effectively modified by dopamine D1 and D2 receptor blockade.

Animals↗
PubMed1994

Adrenalectomy alters discrete galanin mRNA levels in the hypothalamus and mesencephalon of the rat.

Using solution and in situ hybridization techniques we have studied the effects of adrenalectomy with or without restitution therapy with corticosterone on galanin mRNA levels in discrete regions of the male rat brain. Galanin peptide levels were also measured using a radioimmunoassay. The solution hybridization showed a two-fold increase in galanin mRNA 7 days, but not 14 days, after adrenalectomy in the preoptic area including the hypothalamic paraventricular nucleus (PVN). No changes were observed in the mediobasal hypothalamus including the arcuate nucleus. In situ hybridization showed that the increase in galanin mRNA was localized to the PVN and that the arcuate nucleus was not affected. The changes observed could be fully counteracted by corticosterone treatment. Radioimmunoassay showed decreased galanin levels in the median eminence 14 days, but not 7 days, after adrenalectomy and increased levels in the anterior pituitary and neurointermediate lobe. The results give evidence for a regional regulation of galanin gene expression and galanin peptide synthesis by adrenocortical steroids.

Adrenalectomy↗
PubMed1994

Adrenalectomy increases the number of substance P and somatostatin immunoreactive nerve cells in the rat lumbar dorsal root ganglia.

Using an immunocytochemical technique we have analyzed changes in substance P, somatostatin, calcitonin gene-related peptide, and galanin immunoreactivity pattern in the rat dorsal root ganglia. After 7 days of adrenalectomy, sham operated rats were compared with adrenalectomized animals either receiving a daily intraperitoneal injection of 10 mg/kg b.wt. corticosterone or vehicle. Three lumbar ganglia from each animal were blocked, serially cut, and immunostained for each neuropeptide by means of the biotin-avidin-peroxidase technique. A systematic sampling of immunoreactive ganglion cells was performed and the sample number of immunoreactive ganglion cells was calculated. After adrenalectomy, the number of substance P and somatostatin immunoreactive ganglion cells markedly increased ((means +/- S.E.M.): 245 +/- 68 versus 123 +/- 12 for sham operated animals, P < 0.01 (substance P) and 42 +/- 8 as compared to 22 +/- 9 for sham operated animals, P < 0.01 (somatostatin)). No significant changes were found in the number of calcitonin gene-related peptide and galanin immunoreactive cells after adrenalectomy. These results suggest that adrenal steroid hormones may reduce the synthesis of both substance P and somatostatin in the dorsal root ganglion cells. Daily treatment with a high dose of corticosterone, mimicking its serum levels after stress, failed to prevent the increase of peptide contents after adrenalectomy. These observations also indicate that a tonic action of corticosterone on mineralocorticoid receptors may be crucial for peptide regulation in the spinal ganglia. These results may be of relevance to adrenalectomy induced changes in sensory mechanisms, neurogenic inflammation and pain transmission and to a role of substance P and somatostatin in these processes.

Adrenalectomy↗
PubMed1994

Evidence for a regional distribution of hyaluronic acid in the rat brain using a highly specific hyaluronic acid recognizing protein.

By means of a highly specific hyaluronic acid-recognizing protein the localization and regional distribution of hyaluronic acid was demonstrated in the tel- and diencephalon and in the midbrain of the adult rat nervous system. Histochemistry revealed labeling associated with the plasma membrane in highly discrete nerve cell bodies of the frontoparietal cortex, the red nucleus, the zona reticulata of the substantia nigra, the oculomotor nucleus and the reticular thalamic nucleus. A strong labeling without association with perikarya was demonstrated in the subgranular zone of the dentate gyrus of the hippocampal formation. The present results open up the possibility that the hyaluronic acid found in high concentrations associated with some perikarya may have a special role in plasticity responses in these discrete nerve cell populations.

Animals↗
PubMed1994

Subpopulations of primary sensory neurons show coexistence of neuropeptides and glucocorticoid receptors in the rat spinal and trigeminal ganglia.

The coexistence of the neuropeptides substance P, calcitonin gene-related peptide, galanin, somatostatin and neuropeptide Y with glucocorticoid receptors was studied in neurons of the rat lumbar dorsal root and trigeminal ganglia by means of the double immunofluorescence technique. Based on analysis of microphotographs, about one-third of the populations of nerve cells (small and large) containing substance P or calcitonin gene-related peptide immunoreactivity (IR) showed nuclear glucocorticoid receptor IR. A similar pattern was observed within the dorsal root and trigeminal ganglia. Furthermore, within the lumbar dorsal root ganglia 50% of the small neurons, containing galanin IR, possessed nuclear glucocorticoid receptor IR of moderate intensity. Glucocorticoid receptor IR was not observed in the galanin immunoreactive neurons of the trigeminal ganglion neither in the somatostatin and NPY immunoreactive neurons of both the dorsal root and the trigeminal ganglia. The results provide a chemical anatomical basis for a direct regulation by glucocorticoids of distinct populations of substance P and calcitonin gene-related peptide immunoreactive nerve cells in the lumbar spinal and trigeminal ganglia and of galanin immunoreactive nerve cells of the spinal but not of the trigeminal ganglia.

Animals↗
PubMed1994

On the regional distribution of heparan sulfate proteoglycan immunoreactivity in the rat brain.

By means of two monoclonal antibodies specific for heparan sulfate (HS)-related epitopes, one (10E4) against native HS chains and one (3G10) against desaturated uronates, a highly regional and differential distribution of these two epitopes have been observed in the adult rat brain. The 10E4 epitope immunoreactivity (IR) is mainly found in the substantia nigra, the red nucleus and the subgranular zone of the dentate gyrus, while the 3G10 epitope IR is mainly found in the CA2 area of the hippocampal formation and the pyramdial cells in the layer V of the frontoparietal cortex. The codistribution of both types of IRs with basic fibroblast growth factor (bFGF, FGF-2) in neurons and astroglia supports the notion that heparan sulfate proteoglycans (HSPG) in the extracellular matrix may serve as a site for storage of bFGF and assist in the bFGF-induced activation of the high-affinity FGF receptors linked to astroglia and neurons in these discrete areas.

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine↗
PubMed1994

Galanin-(1-15), but not galanin-(1-29), modulates 5-HT1A receptors in the dorsal hippocampus of the rat brain: possible existence of galanin receptor subtypes.

The aim of the present study was to evaluate whether galanin-(1-29) and galanin-(1-15) can modulate the 5-hydroxytryptamine1A (5-HT1A) receptors using [3H]8-OH-2-(di-n-propylamino)-tetralin ([3H]8-OH-DPAT) as a radioligand. Membrane preparations of the dorsal hippocampus, an area having the recently described [125I]galanin-(1-15) fragment binding sites, but having very few porcine [125I]galanin-(1-29) binding sites, were used. Galanin-(1-15) produced a concentration-dependent increase in the Kd value of [3H]8-OH-DPAT with a maximum effect of approximately 65% at 3 nM of galanin-(1-15), whereas galanin-(1-29) had no effect. This increase of the Kd value of [3H]8-OH-DPAT could be completely counteracted by the putative galanin antagonist M35 (1 nM). The Bmax values of [3H]8-OH-DPAT were not affected in any experiment. In conclusion, the present results give further evidence for the existence of a galanin receptor subtype mainly recognizing N-terminal galanin fragments, also having the ability to reduce the affinity of 5-HT1A receptors.

Animals↗